SCHEMBL2856155

SCHEMBL2856155

NC(=O)C(Cc1ccc(Cl)c(Cl)c1)c1ccccn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.48
NPC1 O15118 4/20 0.48
ALDH1A1 P00352 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C19 P33261 1/20 0.48
S1PR2 O95136 1/20 0.44
S1PR4 O95977 1/20 0.44
S1PR3 Q99500 1/20 0.44
PNMT P11086 1/20 0.44
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
RAB9A P51151 3/20 0.41
GRM4 Q14833 1/20 0.41
MAPT P10636 4/20 0.41
GLA P06280 1/20 0.41
HTT P42858 1/20 0.41
TRPV3 Q8NET8 1/20 0.41
EPHX1 P07099 1/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2854300 0.80 EPHX1 (0.46) NPC1ALDH1A1CYP2C19MEN1KMT2A
SCHEMBL2854491 0.80 ALDH1A1 (0.47) NPC1ALDH1A1CYP2C19MEN1KMT2A
SCHEMBL20473311 0.79 PNMT (0.54) NPSR1NPC1ALDH1A1CYP2D6CYP2C19
SCHEMBL2854480 0.77 EPHX1 (0.46) ALDH1A1CYP2D6CYP2C19PNMTMEN1
SCHEMBL2857169 0.75 RAB9A (0.47) NPC1ALDH1A1CYP2D6MEN1KMT2A
SCHEMBL1127590 0.72 KMT2A (0.46) NPSR1NPC1CYP2D6KMT2ARAB9A
SCHEMBL31741261 0.72 ALDH1A1 (0.50) NPSR1ALDH1A1CYP2D6CYP2C19MEN1
SCHEMBL11877321 0.72 CYP2C19 (0.44) NPSR1ALDH1A1CYP2C19MEN1KMT2A
SCHEMBL2432679 0.72 ALDH1A1 (0.50) NPSR1ALDH1A1CYP2D6CYP2C19MEN1
SCHEMBL3373228 0.71 KMT2A (0.45) NPSR1NPC1ALDH1A1CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP disclosed
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 US disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES SCN3A, TRPV3, HCN3 NPSR1 420/4885NPC1 3322/4885ALDH1A1 3589/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 NPSR1 420/4885NPC1 3322/4885ALDH1A1 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.